Efficacy of rituximab in refractory RRMS.
Pierre DurozardAdil MaaroufClémence BoutiereAurelie RuetBruno BrochetBertrand AudoinClarisse Carra-DallierePierre LabaugeGuillaume MatheyMarc DebouverieCaroline PapeixElisabeth MaillartCatherine LubetzkiCaroline BensaOlivier GoutClaire GiannesiniBruno StankoffJonathan CironDavid BrassatJean PelletierAudrey Rico LamyBertrand AudoinPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2018)
This study provides level IV evidence that rituximab reduces clinical and MRI disease activity in patients with active RRMS despite immunosuppressive DMT.